Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers

Psychopharmacology

Volumn 218, Issue 4, 2011, Pages 733-748

  Veselinović, Tanja ^a,b   Schorn, Holger ^a,b   Vernaleken, Ingo ^a,b   Schiffl, Katharina ^a   Hiemke, Christoph ^d   Zernig, Gerald ^e   Gur, Ruben ^c   Gründer, Gerhard ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JARA Translational Brain Medicine   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotics; Aripiprazole; Dopamine; Haloperidol; Healthy volunteers; Psychopathology; Reserpine

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PLACEBO; RESERPINE;

ACCOMMODATION DISORDER; ADULT; AGITATION; ALERTNESS; AMBIVALENCE; AMNESIA; ANHEDONIA; ANOMIA; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; ATTENTION DISTURBANCE; BODY TEMPERATURE DISORDER; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DISORIENTATION; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EMOTIONAL DISORDER; ENDURANCE; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; FATIGUE; FEMALE; FLASH SYMPTOM; HEARTBURN; HUMAN; HUMAN EXPERIMENT; HYPERSALIVATION; INCREASED APPETITE; IRRITABILITY; MALE; MENTAL CONCENTRATION; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE HYPOTONIA; MUSCLE SPASM; MYALGIA; NASAL MUCOSA SWELLING; NAUSEA; NERVOUSNESS; NORMAL HUMAN; NOSE DISEASE; OBSESSION; OROFACIAL MUSCULAR CRAMP; PARESTHESIA; PERCEPTION DISORDER; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SPEECH DISORDER; STOMACH PAIN; SWEATING; SYMPTOMATOLOGY; TACHYCARDIA; THORAX PAIN; THOUGHT DISORDER; TONGUE MUSCULAR CRAMP; TREMOR; UNPLEASANT DREAM; VERTIGO; VOMITING; WEAKNESS; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOPAMINE; FEMALE; HALOPERIDOL; HUMANS; MALE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RESERPINE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 82955213536     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2368-3     Document Type: Article

References (88)

1. A Abi-Dargham 2004 Do we still believe in the dopamine hypothesis? New data bring new evidence Int J Neuropsychopharmacol 7 Suppl 1 S1 S5 14972078 10.1017/S1461145704004110 1:CAS:528:DC%2BD2cXhtlKgsr8%3D
2. American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders-DSM-III, 3rd edn. American Psychiatric Association, Washington
3. AG Awad 1993 Subjective response to neuroleptics in schizophrenia Schizophr Bull 19 3 609 618 7901897 1:STN:280:DyaK2c%2FltlGlsw%3D%3D (Pubitemid 23272627)
4. AG Awad LN Voruganti 2004 Impact of atypical antipsychotics on quality of life in patients with schizophrenia CNS Drugs 18 13 877 893 15521791 10.2165/00023210-200418130-00004 1:CAS:528:DC%2BD2MXhs1yntg%3D%3D (Pubitemid 39612017)
5. AG Awad LN Voruganti 2005 Neuroleptic dysphoria: revisiting the concept 50 years later Acta Psychiatr Scand Suppl 427 6 13 15877718 10.1111/j.1600-0447. 2005.00539.x (Pubitemid 40780194)
6. FJ Ayd Jr 1958 Drug-induced depression; fact of fallacy N Y State J Med 58 3 354 356 13504486
7. TR Barnes 1989 A rating scale for drug-induced akathisia Br J Psychiatry 154 672 676 2574607 10.1192/bjp.154.5.672 1:STN:280:DyaK3c%2FovFOrtQ%3D%3D (Pubitemid 19154942)
8. AA Baumeister MF Hawkins SM Uzelac 2003 The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis J Hist Neurosci 12 2 207 220 12953623 10.1076/jhin.12.2.207.15535 (Pubitemid 36944203)
9. P Bech P Allerup LF Gram N Reisby R Rosenberg O Jacobsen A Nagy 1981 The Hamilton depression scale. Evaluation of objectivity using logistic models Acta Psychiatr Scand 63 3 290 299 7015793 10.1111/j.1600-0447.1981.tb00676.x 1:STN:280:DyaL3M3gtlOjtQ%3D%3D (Pubitemid 11137960)
10. A Beck C Ward M Mendelson J Mock Erbaugh 1961 An inventory for measuring depression Arch Gen Psychiatry 4 561 571 13688369 1:STN:280: DyaF3c%2FgslKisg%3D%3D
11. RH Belmaker D Wald 1977 Haloperidol in normals Br J Psychiatry 131 222 223 263590 10.1192/bjp.131.2.222b 1:STN:280:DyaL2c3lvVahsA%3D%3D
12. JL Berlant 1986 Neuroleptics and reserpine in refractory psychoses J Clin Psychopharmacol 6 3 180 184 2872238 10.1097/00004714-198606000-00013 1:STN:280:DyaL283isVOhsw%3D%3D (Pubitemid 16021624)
13. D Bhugra 2005 The global prevalence of schizophrenia PLoS Med 2 5 e141 10.1371/journal.pmed.0020151 quiz e175 (Pubitemid 40973519)
14. RA Bressan DC Costa HM Jones PJ Ell LS Pilowsky 2002 Typical antipsychotic drugs-D(2) receptor occupancy and depressive symptoms in schizophrenia Schizophr Res 56 1-2 31 36 12084417 10.1016/S0920-9964(01)00185-2 (Pubitemid 34655465)
15. AL Brody RE Olmstead ED London J Farahi JH Meyer P Grossman GS Lee J Huang EL Hahn MA Mandelkern 2004 Smoking-induced ventral striatum dopamine release Am J Psychiatry 161 7 1211 1218 15229053 10.1176/appi.ajp.161.7.1211 (Pubitemid 38859170)
16. S Browne J Garavan M Gervin M Roe C Larkin E O'Callaghan 1998 Quality of life in schizophrenia: insight and subjective response to neuroleptics J Nerv Ment Dis 186 74 78 9484306 10.1097/00005053-199802000-00002 1:STN:280: DyaK1c7ksFejsg%3D%3D (Pubitemid 28117637)
17. RW Buchanan 2007 Persistent negative symptoms in schizophrenia: an overview Schizophr Bull 33 4 1013 1022 17099070 10.1093/schbul/sbl057 (Pubitemid 47216643)
18. DR Burt I Creese SH Snyder 1977 Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain Science 196 4287 326 328 847477 10.1126/science.847477 1:CAS:528:DyaE2sXhvVegtrc%3D (Pubitemid 8076966)
19. WT Carpenter Jr DW Heinrichs AM Wagman 1988 Deficit and nondeficit forms of schizophrenia: the concept Am J Psychiatry 145 5 578 583 3358462
20. MA Davies DJ Sheffler BL Roth 2004 Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology CNS Drug Rev 10 4 317 336 15592581 10.1111/j.1527-3458.2004.tb00030.x 1:CAS:528:DC%2BD2MXhsFejsLo%3D (Pubitemid 40128915)
21. L De Haan M van Bruggen J Lavalaye J Booij PM Dingemans D Linszen 2003 Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study Am J Psychiatry 160 2 303 309 12562577 10.1176/appi.ajp.160. 2.303 (Pubitemid 41110456)
22. L De Haan J Lavalaye M van Bruggen L van Nimwegen J Booij T van Amelsvoort D Linszen 2004 Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications Can J Psychiatry 49 5 290 296 15198464 (Pubitemid 38724633)
23. L De Haan J Booij J Lavalye T van Amelsvoort D Linszen 2005 Subjective experiences during dopamine depletion Am J Psychiatry 162 9 1755 16135643
24. Dilling H, Mombour W, Schmidt MH (2002) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien (Auflage: 5). Huber, Bern
25. S Dollfus M Petit 1995 Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in acute phase Eur Psychiatry 8 97 106 10.1016/0924-9338(96)80320-8
26. C Domecq CA Naranjo I Ruiz U Busto 1980 Sex-related variations in the frequency and characteristics of adverse drug reactions Int J Clin Pharmacol Ther Toxicol 18 8 362 366 7409941 1:STN:280:DyaL3M%2Fgs1SltA%3D%3D (Pubitemid 10090065)
27. BW Dunlop CB Nemeroff 2007 The role of dopamine in the pathophysiology of depression Arch Gen Psychiatry 64 3 327 337 17339521 10.1001/archpsyc.64.3.327 1:CAS:528:DC%2BD2sXjs1yntLY%3D (Pubitemid 46376789)
28. L Farde A-L Nordström F-A Wiesel S Pauli C Halldin G Sedvall 1992 Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine-relation to extrapyramidal side effects Arch Gen Psychiatry 49 538 544 1352677 1:STN:280:DyaK38zivVKgug%3D%3D
29. First MB, Spitzer RL, Gibbon M, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). Biometrics Research, New York State Psychiatric Institute. New York, NY
30. PB Fitzgerald S Kapur G Remington P Roy RB Zipursky 2000 Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels Psychopharmacology (Berl) 149 1 1 5 10.1007/s002139900333 1:CAS:528: DC%2BD3cXis12ktr8%3D (Pubitemid 30187359)
31. JS Fowler J Logan GJ Wang ND Volkow 2003 Monoamine oxidase and cigarette smoking Neurotoxicology 24 1 75 82 12564384 10.1016/S0161-813X(02)00109-2 1:CAS:528:DC%2BD38XpsFSls7c%3D (Pubitemid 36091163)
32. G Gründer A Carlsson DF Wong 2003 Mechanism of new antipsychotic medications: occupancy is not just antagonism Arch Gen Psychiatry 60 10 974 977 14557141 10.1001/archpsyc.60.10.974 (Pubitemid 37222078)
33. G Gründer C Fellows H Janouschek T Veselinovic C Boy A Bröcheler KM Kirschbaum S Hellmann KM Spreckelmeyer C Hiemke F Rösch WM Schaefer I Vernaleken 2008 Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study Am J Psychiatry 165 8 988 995 18381901 10.1176/appi.ajp.2008.07101574
34. SM Halstead TR Barnes JC Speller 1994 Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia Br J Psychiatry 164 2 177 183 7909711 10.1192/bjp.164.2.177 1:STN:280: DyaK2c3ivVWltg%3D%3D (Pubitemid 24077352)
35. M Hamilton 1960 A rating scale for depression J Neurol Neurosurg Psychiatry 23 56 62 14399272 10.1136/jnnp.23.1.56 1:STN:280:DyaF3c7ltFyksw%3D%3D
36. D Healy M Savage 1998 Reserpine exhumed Br J Psychiatry 172 376 378 9747395 10.1192/bjp.172.5.376 1:STN:280:DyaK1cvhvFGgsA%3D%3D (Pubitemid 28204543)
37. JP Henry D Botton C Sagne MF Isambert C Desnos V Blanchard R Raisman-Vozari E Krejci J Massoulie B Gasnier 1994 Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules J Exp Biol 196 251 262 7823026 1:CAS:528:DyaK2MXivFWrtbY%3D
38. PB Jones TR Barnes L Davies G Dunn H Lloyd KP Hayhurst RM Murray A Markwick SW Lewis 2006 Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 10 1079 1087 17015810 10.1001/archpsyc.63.10.1079 1:CAS:528:DC%2BD28XhtFKhtrzP (Pubitemid 44498387)
39. K Kannari H Tanaka T Maeda M Tomiyama T Suda M Matsunaga 2000 Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation J Neurochem 74 1 263 269 10617128 10.1046/j.1471-4159.2000.0740263.x 1:CAS:528:DC%2BD3cXlt12l (Pubitemid 30012777)
40. S Kapur JJ Mann 1992 Role of the dopaminergic system in depression Biol Psychiatry 32 1 1 17 1391289 10.1016/0006-3223(92)90137-O 1:CAS:528: DyaK3sXjs1Ontw%3D%3D
41. S Kapur G Remington C Jones A Wilson J DaSilva S Houle R Zipursky 1996 High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study Am J Psychiatry 153 7 948 950 8659621 1:STN:280:DyaK283lvFCrtA%3D%3D (Pubitemid 26225470)
42. SR Kay A Fiszbein LA Opler 1987 The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 2 261 276 3616518 1:STN:280:DyaL2s3ptF2huw%3D%3D (Pubitemid 18039085)
43. KM Kirschbaum MJ Muller J Malevani A Mobascher C Burchardt M Piel C Hiemke 2008 Serum levels of aripiprazole and dehydroaripiprazole, clinical response, and side effects World J Biol Psychiatry 9 3 212 218 17853280 10.1080/15622970701361255
44. BB Kumar 1979 An unusual case of akathisia Am J Psychiatry 136 8 1088 464141 1:STN:280:DyaE1M3ivFCguw%3D%3D (Pubitemid 9221664)
45. G Laakmann D Blaschke H Hippius S Schewe 1988 Double-blind randomized trial of the benzodiazepine derivative metaclazepam as compared with placebo treatment of outpatients with anxiety syndromes Pharmacopsychiatry 21 3 136 143 2900514 10.1055/s-2007-1014665 1:STN:280:DyaL1czgtl2quw%3D%3D
46. SZ Langer 1980 Presynaptic regulation of the release of catecholamines Pharmacol Rev 32 4 337 362 6267618 1:CAS:528:DyaL3MXkslOntLw%3D
47. M Laruelle CD D'Souza RM Baldwin A Abi-Dargham SJ Kanes CL Fingado JP Seibyl SS Zoghbi MB Bowers P Jatlow DS Charney RB Innis 1997 Imaging D2 receptor occupancy by endogenous dopamine in humans Neuropsychopharmacology 17 3 162 174 9272483 10.1016/S0893-133X(97)00043-2 1:CAS:528:DyaK2sXls1Oru7Y%3D (Pubitemid 27365957)
48. Lehrl S (1989) Mehrfachwahl-Wortschatz-Intelligenztest MWT-B (Multiple-choice intelligence test). Perimed, Erlangen
49. G Lemieux A Davignon J Genest 1956 Depressive states during Rauwolfia therapy for arterial hypertension: a report of 30 cases Can Med Assoc J 74 7 522 526 13304797 1:STN:280:DyaG28%2FlslWnug%3D%3D
50. Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G (2006) Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 10(17), iii-iv, ix-xi, 1-165
51. JP Lindenmayer R Bernstein-Hyman S Grochowski 1994 A new five factor model of schizophrenia Psychiatr Q 65 4 299 322 7831416 10.1007/BF02354306 1:STN:280:DyaK2M7jt1Ogug%3D%3D
52. JP Lindenmayer R Bernstein-Hyman S Grochowski N Bark 1995 Psychopathology of schizophrenia: initial validation of a 5-factor model Psychopathology 28 1 22 31 7871117 10.1159/000284896 1:STN:280:DyaK2M7nsF2isg%3D%3D (Pubitemid 24368666)
53. W Maier D Lichtermann J Minges R Heun J Hallmayer O Benkert 1992 Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? Evidence from a family study Am J Psychiatry 149 1666 1673 1443243 1:STN:280:DyaK3s%2Fnt1Cquw%3D%3D
54. D Mamo A Graff R Mizrahi CM Shammi F Romeyer S Kapur 2007 Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study Am J Psychiatry 164 9 1411 1417 17728427 10.1176/appi.ajp.2007.06091479 (Pubitemid 47461142)
55. CD Marsden P Jenner 1980 The pathophysiology of extrapyramidal side-effects of neuroleptic drugs Psychol Med 10 1 55 72 6104342 10.1017/S003329170003960X 1:CAS:528:DyaL3cXhvFSrt7k%3D (Pubitemid 11141134)
56. DD Miller SN Caroff SM Davis RA Rosenheck JP McEvoy BL Saltz S Riggio MH Chakos MS Swartz RS Keefe TS Stroup JA Lieberman Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators 2008 Extrapyramidal side-effects of antipsychotics in a randomised trial Br J Psychiatry 193 4 279 288 18827289 10.1192/bjp.bp.108.050088
57. J Moncrieff D Cohen JP Mason 2009 The subjective experience of taking antipsychotic medication: a content analysis of Internet data Acta Psychiatr Scand 120 2 102 111 19222405 10.1111/j.1600-0447.2009.01356.x 1:STN:280:DC%2BD1MvnvFWiuw%3D%3D
58. M Mula S Pini GB Cassano 2007 The neurobiology and clinical significance of depersonalization in mood and anxiety disorders: a critical reappraisal J Affect Disord 99 1-3 91 99 16997382 10.1016/j.jad.2006.08.025 (Pubitemid 46290666)
59. D Naber S Moritz B Andresen D Jacobsen K Mersmann U Wilke M Lambert D Naber M Krausz 2001 Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics Eur Psychiatry 16 6 354 361 11585716 10.1016/S0924-9338(01)00591-0 (Pubitemid 32928950)
60. JW Newcomer LS Miller WO Faustman MW Wetzel GP Vogler JG Csernansky 1994 Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria Br J Psychiatry 164 6 834 838 7952993 10.1192/bjp.164.6.834 1:STN:280:DyaK2M%2FktVOksA%3D%3D (Pubitemid 24186907)
61. AL Nordström L Farde FA Wiesel K Forslund S Pauli C Halldin G Uppfeldt 1993 Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients Biol Psychiatry 33 4 227 235 8097114 10.1016/0006-3223(93)90288-O (Pubitemid 23091497)
62. MC Nowycky RH Roth 1977 Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate Naunyn Schmiedebergs Arch Pharmacol 300 3 247 254 600312 1:CAS:528:DyaE1cXhs1Cis7g%3D (Pubitemid 8224542)
63. JT Pan MJ Hooth KJ Lookingland KE Moore TA Marks 1993 Comparison of the effects of losulazine and reserpine on central aminergic neurons Toxicol Appl Pharmacol 123 1 26 33 8236258 10.1006/taap.1993.1217 1:CAS:528: DyaK2cXksFGgug%3D%3D (Pubitemid 23343168)
64. V Peralta MJ Cuesta 1999 Negative, parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited Schizophr Res 40 3 245 253 10638863 10.1016/S0920-9964(99)00047-X 1:STN:280:DC%2BD3c7gt1Cjsw%3D%3D
65. BG Pollock 1994 Recent developments in drug metabolism of relevance to psychiatrists Harv Rev Psychiatry 2 204 213 9384903 10.3109/10673229409017138 1:STN:280:DyaK1c%2Fjs1yhtA%3D%3D (Pubitemid 24372960)
66. M Poyurovsky A Weizman 1997 Serotonergic agents in the treatment of acute neuroleptic-induced akathisia: open-label study of buspirone and mianserin Int Clin Psychopharmacol 12 5 263 268 9466160 10.1097/00004850-199709000-00003 1:STN:280:DyaK1c7islejug%3D%3D (Pubitemid 28021753)
67. JG Ramaekers JW Louwerens ND Muntjewerff H Milius A de Bie P Rosenzweig A Patat JF O'Hanlon 1999 Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic J Clin Psychopharmacol 19 3 209 221 10350027 10.1097/00004714-199906000-00003 1:CAS:528:DyaK1MXjs1ant70%3D (Pubitemid 29233015)
68. Randrup A, Munkvad L, Fog R et al (1975) Mania, depression, and brain dopamine. In: Essman WB, Valzelli L (eds) Current developments in psychopharmacology. Spectrum Publications, New York, pp 207-229
69. BL Roth DJ Sheffler WK Kroeze 2004 Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat Rev Drug Discov 3 4 353 359 15060530 10.1038/nrd1346 1:CAS:528:DC%2BD2cXis1Gkt78%3D (Pubitemid 38499762)
70. H Saeedi G Remington BK Christensen 2006 Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood Schizophr Res 85 1-3 222 231 16679001 10.1016/j.schres.2006.03.033 (Pubitemid 43947541)
71. O Schoots P Seeman HC Guan AD Paterson HH Van Tol 1995 Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats Eur J Pharmacol 289 1 67 72 7781713 10.1016/0922-4106(95)90169-8 1:CAS:528:DyaK2MXktFertL8%3D
72. ED Shaw JJ Mann PJ Weiden LM Sinsheimer RD Brunn 1986 A case of suicidal and homicidal ideation and akathisia in a double-blind neuroleptic crossover study J Clin Psychopharmacol 6 3 196 197 2872240 10.1097/00004714-198606000- 00024 1:STN:280:DyaL283isVOhtQ%3D%3D
73. GM Simpson JWS Angus 1970 A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 212 11 19 4917967 10.1111/j.1600-0447.1970.tb02066.x 1:STN:280:DyaE3c3ptFWjuw%3D%3D
74. PF Sullivan MC Neale KS Kendler 2000 Genetic epidemiology of major depression: review and meta-analysis Am J Psychiatry 157 1552 1562 11007705 10.1176/appi.ajp.157.10.1552 1:STN:280:DC%2BD3M%2FgvVOitQ%3D%3D
75. LK Tremblay CA Naranjo SJ Graham N Herrmann HS Mayberg S Hevenor UE Busto 2005 Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe Arch Gen Psychiatry 62 1228 1236 16275810 10.1001/archpsyc.62.11.1228 (Pubitemid 41586922)
76. TM Tzschentke 2001 Pharmacology and behavioral pharmacology of the mesocortical dopamine system Prog Neurobiol 63 3 241 320 11115727 10.1016/S0301-0082(00)00033-2 1:CAS:528:DC%2BD3cXoslCks7o%3D
77. T Van Putten 1974 Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31 1 67 72 4151750
78. NP Verhoeff S Kapur D Hussey M Lee B Christensen C Psych G Papatheodorou RB Zipursky 2001 A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects Neuropsychopharmacology 25 2 213 223 11425505 10.1016/S0893-133X(01)00231-7 1:CAS:528:DC%2BD3MXks1OgtLY%3D (Pubitemid 32566343)
79. NP Verhoeff BK Christensen D Hussey M Lee G Papatheodorou L Kopala Q Rui RB Zipursky S Kapur 2003 Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study Pharmacol Biochem Behav 74 2 425 432 12479964 10.1016/S0091-3057(02)01028-6 1:CAS:528:DC%2BD38XptlGitLw%3D (Pubitemid 35449529)
80. I Vernaleken Y Kumakura P Cumming HG Buchholz T Siessmeier P Stoeter MJ Müller P Bartenstein G Gründer 2006 Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge Neuroimage 30 4 1332 1339 16439159 10.1016/j.neuroimage.2005.11.014
81. T Veselinović H Schorn IB Vernaleken K Schiffl M Klomp G Gründer 2011 Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion J Clin Psychopharmacol 31 2 214 220 21346608 10.1097/JCP.0b013e31820e4832
82. L Voruganti AG Awad 2004 Neuroleptic dysphoria: towards a new synthesis Psychopharmacology (Berl) 171 2 121 132 10.1007/s00213-003-1648-y 1:CAS:528:DC%2BD3sXhtVSjsLbO (Pubitemid 38134648)
83. L Voruganti P Slomka P Zabel G Costa A So A Mattar AG Awad 2001 Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging Neuropsychopharmacology 25 5 642 650 11682247 10.1016/S0893- 133X(01)00263-9 1:CAS:528:DC%2BD3MXnslCjsb4%3D (Pubitemid 32995946)
84. MM Weissman ES Gershon KK Kidd BA Prusoff JF Leckman E Dibble, et al. 1984 Psychiatric disorders in the relatives of probands with affective disorders: the Yale NIMH collaborative family study Arch Gen Psychiatry 41 13 21 6691780 1:STN:280:DyaL2c7gtlGnug%3D%3D (Pubitemid 14215332)
85. L White PD Harvey L Opler JP Lindenmayer 1997 Empirical assessment of the factorial structure of clinical in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group Psychopathology 30 263 274 9353855 10.1159/000285058 1:STN:280:DyaK1c%2FhsFeisg%3D%3D
86. T Yoshitake S Yoshitake K Fujino H Nohta M Yamaguchi J Kehr 2004 High-sensitive liquid chromatographic method for determination of neuronal release of serotonin, noradrenaline and dopamine monitored by microdialysis in the rat prefrontal cortex J Neurosci Methods 140 1-2 163 168 15589346 10.1016/j.jneumeth.2004.04.041 1:CAS:528:DC%2BD2cXhtVKrt77P (Pubitemid 39625864)
87. Zerssen DV, Köller D-M (1976) Die Befindlichkeitsskala. Parallelformen Bf-S and Bf-Ś.(The well-being scale, Parallelforms Bf-S and Bf-Ś). Beltz, Weinheim
88. J Zhang-Wong M Beiser RB Zipursky G Bean 1998 An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol Psychiatry Res 81 3 333 339 9925184 10.1016/S0165-1781(98)00114-0 1:CAS:528:DyaK1MXhtVKrsb8%3D (Pubitemid 29049060)